{"id":"micardis-anlo","safety":{"commonSideEffects":[{"rate":"3-10%","effect":"Dizziness"},{"rate":"2-5%","effect":"Headache"},{"rate":"2-5%","effect":"Fatigue"},{"rate":"1-3%","effect":"Cough"},{"rate":"1-3%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the angiotensin II receptor, Micardis Anlo reduces the blood pressure by dilating blood vessels and reducing the heart rate. This action also reduces the strain on the heart and kidneys.","oneSentence":"Micardis Anlo is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:13.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07030101","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2026-11","conditions":"Hypertension","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Micardis Anlo","genericName":"Micardis Anlo","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Micardis Anlo is a small molecule that acts as a type-1 angiotensin II receptor antagonist. It is used to treat hypertension, as indicated by clinical trials studying its efficacy and safety in participants with uncontrolled high blood pressure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}